Genitourinary Cancers

The year was 1989, and I was one year away from finishing six years of residency in general surgery and urology.

It took just a minute and a half for a disgruntled patient to leave his deadly mark on a Nevada urology clinic, irreversibly changing the lives of everyone inside.

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

J. Kellogg Parsons, MD, associate professor of surgery (urology), University of California, San Diego, discusses modifiable lifestyle factors associated with bladder cancer.

A genomic analysis of renal cell carcinoma (RCC) has uncovered new clues about the development, growth, and spread of the cancer.

In recent studies, robotic-assisted surgery was explored as a treatment for both prostate and kidney cancers.

I am sure that those of you who attended the AUA meeting in Orlando were struck by the number of presentations on the use of biomarkers and their role in better risk stratification and management of the urologic oncology patient.

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

When a patient develops advanced prostate cancer, that doesn't mean his urologist needs to bid him farewell.